{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:25:49Z","timestamp":1787257549825,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.carrev.2026.06.009","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:28:31Z","timestamp":1781764111000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Expert perspectives on de-escalation of antiplatelet therapy \u2013 Beyond the Guidelines: Insights from the Cardiovascular Research Technologies 2026 meeting"],"prefix":"10.1016","volume":"89","author":[{"given":"Jason","family":"Galo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas Rodr\u00edguez","family":"Granillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo M.","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Mhaimeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Baber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Marmagkiolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Kesarwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsik","family":"Ben-Dor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Waksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2026.06.009_bb0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.carrev.2025.07.007","article-title":"Sex differences in high-potency P2Y12 inhibitors prescription among patients with acute myocardial infarction","volume":"83","author":"Mansoor","year":"2026","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.carrev.2026.06.009_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.carrev.2025.05.007","article-title":"Ticagrelor vs. clopidogrel in bivalirudin-treated patients with STEMI undergoing primary PCI: the BRIGHT-4 trial","volume":"83","author":"Li","year":"2026","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.carrev.2026.06.009_bb0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.carrev.2025.10.017","article-title":"Role of intravenous P2Y12 inhibition in high-risk percutaneous coronary intervention","volume":"84","author":"Prasad","year":"2026","journal-title":"Cardiovasc Revasc Med"},{"issue":"9","key":"10.1016\/j.carrev.2026.06.009_bb0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2026.06.009_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001328","article-title":"ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2026.06.009_bb0030","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.carrev.2026.06.009_bb0035","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.carrev.2026.06.009_bb0040","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.jcin.2025.05.044","article-title":"Aspirin or P2Y(12) inhibitor monotherapy after percutaneous coronary intervention for acute coronary syndromes","volume":"18","author":"Laudani","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"issue":"10508","key":"10.1016\/j.carrev.2026.06.009_bb0045","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","article-title":"Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis","volume":"406","author":"Valgimigli","year":"2025","journal-title":"Lancet"},{"issue":"10486","key":"10.1016\/j.carrev.2026.06.009_bb0050","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(25)00449-0","article-title":"Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial","volume":"405","author":"Choi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2026.06.009_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-082561","article-title":"P2Y(12) inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials","volume":"389","author":"Giacoppo","year":"2025","journal-title":"Bmj"},{"issue":"10293","key":"10.1016\/j.carrev.2026.06.009_bb0060","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.carrev.2026.06.009_bb0065","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jacc.2023.07.031","article-title":"Comparison of antiplatelet monotherapies after percutaneous coronary intervention according to clinical, ischemic, and bleeding risks","volume":"82","author":"Yang","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"10127","key":"10.1016\/j.carrev.2026.06.009_bb0070","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.carrev.2026.06.009_bb0075","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.carrev.2026.06.009_bb0080","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jacc.2019.11.056","article-title":"Ticagrelor with or without aspirin after PCI: the TWILIGHT platelet substudy","volume":"75","author":"Baber","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.carrev.2026.06.009_bb0085","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jcin.2020.12.005","article-title":"Stent thrombosis risk over time on the basis of clinical presentation and platelet reactivity: analysis from ADAPT-DES","volume":"14","author":"Chau","year":"2021","journal-title":"Cardiovascular Interventions"},{"issue":"15","key":"10.1016\/j.carrev.2026.06.009_bb0090","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.jacc.2017.08.018","article-title":"Characterization of the average daily ischemic and bleeding risk after primary PCI for STEMI","volume":"70","author":"Giustino","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.carrev.2026.06.009_bb0095","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa2507980","article-title":"Early withdrawal of aspirin after PCI in acute coronary syndromes","volume":"393","author":"Guimar\u00e3es","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.carrev.2026.06.009_bb0100","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacc.2025.10.058","article-title":"Potent P2Y(12) inhibitor monotherapy vs DAPT after PCI in patients with and without STEMI: the NEO-MINDSET substudy","volume":"87","author":"Tavares","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.carrev.2026.06.009_bb0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2026.06.009_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.amjcard.2024.10.038","article-title":"Short versus one-year dual antiplatelet therapy after percutaneous coronary intervention: an updated meta-analysis","volume":"237","author":"Joseph","year":"2025","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.carrev.2026.06.009_bb0115","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2025.05.010","article-title":"Recurrent events analysis of MASTER DAPT: total ischemic and bleeding events after abbreviated vs prolonged DAPT in HBR patients","volume":"86","author":"Bongiovanni","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.carrev.2026.06.009_bb0120","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jacc.2022.07.016","article-title":"Abbreviated antiplatelet therapy after coronary stenting in patients with myocardial infarction at high bleeding risk","volume":"80","author":"Smits","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.carrev.2026.06.009_bb0125","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.carrev.2026.06.009_bb0130","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jamacardio.2025.5057","article-title":"Ticagrelor vs prasugrel in patients with diabetes and multivessel coronary artery disease: the TUXEDO-2 randomized clinical trial","volume":"11","author":"Bangalore","year":"2026","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.carrev.2026.06.009_bb0135","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4244\/EIJ-E-26-00004","article-title":"Prasugrel should be preferred over ticagrelor in acute coronary syndromes: pros and cons","volume":"22","author":"Angiolillo","year":"2026","journal-title":"EuroIntervention"},{"key":"10.1016\/j.carrev.2026.06.009_bb0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2026.1128","article-title":"Efficacy and safety of prasugrel, ticagrelor, or clopidogrel after percutaneous coronary intervention: a systematic review and meta-analysis","author":"Maqsood","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.carrev.2026.06.009_bb0145","doi-asserted-by":"crossref","unstructured":"Valgimigli M, Hong SJ, Gragnano F, et al. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet 2024;404(10456):937\u2013948. (In eng). DOI: https:\/\/doi.org\/10.1016\/s0140-6736(24)01616-7.","DOI":"10.1016\/S0140-6736(24)01616-7"},{"issue":"4","key":"10.1016\/j.carrev.2026.06.009_bb0150","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.carrev.2026.06.009_bb0155","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"Natsuaki","year":"2024","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.carrev.2026.06.009_bb0160","doi-asserted-by":"crossref","first-page":"e796","DOI":"10.4244\/EIJ-D-25-00331","article-title":"One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial","volume":"21","author":"Jang","year":"2025","journal-title":"EuroIntervention"},{"key":"10.1016\/j.carrev.2026.06.009_bb0165","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf1050","article-title":"Prasugrel or ticagrelor monotherapy vs dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndromes: a landmark analysis from the NEOMINDSET trial","author":"Tavares","year":"2025","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.carrev.2026.06.009_bb0170","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/eurheartj\/ehaf009","article-title":"2024 revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention","volume":"46","author":"J\u00fcni","year":"2025","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.carrev.2026.06.009_bb0175","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"issue":"10439","key":"10.1016\/j.carrev.2026.06.009_bb0180","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge","year":"2024","journal-title":"The Lancet"},{"issue":"22","key":"10.1016\/j.carrev.2026.06.009_bb0185","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.jacc.2025.04.046","article-title":"The 2025 ACS guideline update endorses ticagrelor monotherapy\u2265 1 month after DAPT post-PCI: the unbearable lightness of ticagrelor monotherapy","volume":"85","author":"Mehran","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.carrev.2026.06.009_bb0190","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.carrev.2026.06.009_bb0195","series-title":"Brilinta (ticagrelor) Tablets, for Oral Use (NDA 022433)","year":"2024"},{"issue":"22","key":"10.1016\/j.carrev.2026.06.009_bb0200","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.jacc.2025.04.040","article-title":"The 2025 guideline update endorses ticagrelor monotherapy after\u2265 1 month of DAPT post-PCI in patients with ACS: is the evidence conclusive?","volume":"85","author":"Kaul","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"10456","key":"10.1016\/j.carrev.2026.06.009_bb0205","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(24)01678-7","article-title":"Is this the conclusive evidence for ticagrelor monotherapy in acute coronary syndromes?","volume":"404","author":"Stefanini","year":"2024","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.carrev.2026.06.009_bb0210","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jacc.2021.11.035","article-title":"Antithrombotic therapy in patients with atrial fibrillation after acute coronary syndromes or percutaneous intervention","volume":"79","author":"Harskamp","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2026.06.009_bb0215","series-title":"Going polymer free and dual antiplatelet free earlier: the coevolution of stent and pharmacotherapy","first-page":"172","author":"Gibson","year":"2017"},{"issue":"25","key":"10.1016\/j.carrev.2026.06.009_bb0220","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1016\/j.carrev.2026.06.009_bb0225","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1016\/j.carrev.2026.06.009_bb0230","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"10206","key":"10.1016\/j.carrev.2026.06.009_bb0235","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.carrev.2026.06.009_bb0240","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"20","key":"10.1016\/j.carrev.2026.06.009_bb0245","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.120.046534","article-title":"Risk\/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS","volume":"141","author":"Alexander","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.carrev.2026.06.009_bb0250","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.carrev.2026.06.009_bb0255","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.carrev.2026.06.009_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcin.2022.10.023","article-title":"Timing, selection, modulation, and duration of P2Y12 inhibitors for patients with acute coronary syndromes undergoing PCI","volume":"16","author":"Capodanno","year":"2023","journal-title":"Cardiovascular Interventions"},{"issue":"41","key":"10.1016\/j.carrev.2026.06.009_bb0265","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"issue":"10308","key":"10.1016\/j.carrev.2026.06.009_bb0270","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"The Lancet"},{"issue":"17","key":"10.1016\/j.carrev.2026.06.009_bb0275","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"10055","key":"10.1016\/j.carrev.2026.06.009_bb0280","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"The Lancet"},{"issue":"10104","key":"10.1016\/j.carrev.2026.06.009_bb0285","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.carrev.2026.06.009_bb0290","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ahj.2025.02.020","article-title":"Genotype-guided de-escalation and abbreviation of dual antiplatelet therapy in patients with myocardial infarction and high bleeding risk: design and rationale of the investigator-initiated, multicenter, randomized, controlled trial, DAN-DAPT","volume":"285","author":"Jacobsen","year":"2025","journal-title":"American Heart Journal"},{"key":"10.1016\/j.carrev.2026.06.009_bb0295","series-title":"AI-Driven Personalization of Dual Antiplatelet Therapy Duration Post-PCI: A Novel Approach Balancing Ischemic and Bleeding Risks in the UAE Population","author":"Iftikhar","year":"2025"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838926002745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838926002745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T19:48:27Z","timestamp":1787255307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838926002745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":59,"alternative-id":["S1553838926002745"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2026.06.009","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert perspectives on de-escalation of antiplatelet therapy \u2013 Beyond the Guidelines: Insights from the Cardiovascular Research Technologies 2026 meeting","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2026.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}